GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » PB Ratio

Chiome Bioscience (TSE:4583) PB Ratio : 5.09 (As of May. 27, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-27), Chiome Bioscience's share price is 円114.00. Chiome Bioscience's Book Value per Share for the quarter that ended in Mar. 2024 was 円22.39. Hence, Chiome Bioscience's PB Ratio of today is 5.09.

Good Sign:

Chiome Bioscience Inc stock PB Ratio (=5.09) is close to 1-year low of 5.01

The historical rank and industry rank for Chiome Bioscience's PB Ratio or its related term are showing as below:

TSE:4583' s PB Ratio Range Over the Past 10 Years
Min: 1.53   Med: 3.56   Max: 51.24
Current: 5.09

During the past 13 years, Chiome Bioscience's highest PB Ratio was 51.24. The lowest was 1.53. And the median was 3.56.

TSE:4583's PB Ratio is ranked worse than
76.71% of 1314 companies
in the Biotechnology industry
Industry Median: 2.525 vs TSE:4583: 5.09

During the past 12 months, Chiome Bioscience's average Book Value Per Share Growth Rate was -30.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -34.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -25.60% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -15.90% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Chiome Bioscience was 63.10% per year. The lowest was -34.60% per year. And the median was -21.10% per year.

Back to Basics: PB Ratio


Chiome Bioscience PB Ratio Historical Data

The historical data trend for Chiome Bioscience's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience PB Ratio Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.36 4.20 4.81 6.14

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.64 8.09 6.26 6.14 6.39

Competitive Comparison of Chiome Bioscience's PB Ratio

For the Biotechnology subindustry, Chiome Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's PB Ratio distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's PB Ratio falls into.



Chiome Bioscience PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Chiome Bioscience's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=114.00/22.392
=5.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Chiome Bioscience  (TSE:4583) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Chiome Bioscience PB Ratio Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience (TSE:4583) Business Description

Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines